Jump to main content
Jump to site search

Issue 2, 2016
Previous Article Next Article

Strategies for transporting nanoparticles across the blood–brain barrier

Author affiliations

Abstract

The existence of blood–brain barrier (BBB) hampers the effective treatment of central nervous system (CNS) diseases. Almost all macromolecular drugs and more than 98% of small molecule drugs cannot pass the BBB. Therefore, the BBB remains a big challenge for delivery of therapeutics to the central nervous system. With the structural and mechanistic elucidation of the BBB under both physiological and pathological conditions, it is now possible to design delivery systems that could cross the BBB effectively. Because of their advantageous properties, nanoparticles have been widely deployed for brain-targeted delivery. This review paper presents the current understanding of the BBB under physiological and pathological conditions, and summarizes strategies and systems for BBB crossing with a focus on nanoparticle-based drug delivery systems. In summary, with wider applications and broader prospection the treatment of brain targeted therapy, nano-medicines have proved to be more potent, more specific and less toxic than traditional drug therapy.

Graphical abstract: Strategies for transporting nanoparticles across the blood–brain barrier

Back to tab navigation

Publication details

The article was received on 15 Sep 2015, accepted on 16 Nov 2015 and first published on 08 Dec 2015


Article type: Review Article
DOI: 10.1039/C5BM00383K
Citation: Biomater. Sci., 2016,4, 219-229
  •   Request permissions

    Strategies for transporting nanoparticles across the blood–brain barrier

    T. Zhang, W. Li, G. Meng, P. Wang and W. Liao, Biomater. Sci., 2016, 4, 219
    DOI: 10.1039/C5BM00383K

Search articles by author

Spotlight

Advertisements